Analyzing Cytosorbents Corporation (CTSO) and Agilent Technologies (A)
Cytosorbents Corporation (NASDAQ: CTSO) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.
Earnings and Valuation
This table compares Cytosorbents Corporation and Agilent Technologies’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Cytosorbents Corporation||$9.53 million||18.82||-$11.93 million||($0.32)||-19.53|
|Agilent Technologies||$4.20 billion||5.27||$462.00 million||$1.94||35.46|
Agilent Technologies has higher revenue and earnings than Cytosorbents Corporation. Cytosorbents Corporation is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Cytosorbents Corporation has a beta of -0.59, meaning that its share price is 159% less volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Agilent Technologies pays an annual dividend of $0.53 per share and has a dividend yield of 0.8%. Cytosorbents Corporation does not pay a dividend. Agilent Technologies pays out 27.3% of its earnings in the form of a dividend.
This table compares Cytosorbents Corporation and Agilent Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for Cytosorbents Corporation and Agilent Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytosorbents Corporation currently has a consensus price target of $10.45, suggesting a potential upside of 67.20%. Agilent Technologies has a consensus price target of $67.31, suggesting a potential downside of 2.15%. Given Cytosorbents Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe Cytosorbents Corporation is more favorable than Agilent Technologies.
Institutional and Insider Ownership
6.3% of Cytosorbents Corporation shares are owned by institutional investors. 5.6% of Cytosorbents Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Agilent Technologies beats Cytosorbents Corporation on 9 of the 15 factors compared between the two stocks.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.